Investigational New Drug (IND)-enabling Studies for Sachi Bio's lead molecule
Sachi Bio's lead program NI112 shows excellent Safety-Toxicity, brain-delivery, and biodistribution profile in Investigational New Drug...
top of page
Press releases
- Jan 31
Sachi Bio lead programs to support NASA Missions & counter debilitating diseases on Earth
"Sachi Bio has successfully advanced it's lead program towards translation for a range of neurodegenerative diseases, as well as a...
- Nov 30, 2023
Sachi Bio wins US National Academy of Medicine Sponsored "Healthy Longevity Global Challenge" for Healthy Aging
Starting in 2030, we will witness a historic milestone as the elderly population surpasses the youth for the first time ever. This...
- Nov 10, 2023
Sachi Bio's Research into Exploring Brain Aging in Space flies on SpaceX CRS-29
Sachi Bio is sending samples to International Space Station (ISS) Labs to study the effect of microgravity on brain aging and disease...
- Aug 31, 2023
Sachi Bio presents at ISSR&D Conference as it aims to become the first company in the world to test RNA Therapeutics in Space
Sachi Bio presented data on human brain organoids and their treatment with Nanoligomers, to the space community in the ISSR&D conference...
- Jul 31, 2023
Sachi Bio awarded SBIR Phase III contract from NASA for Rapid, Low-Cost Drug-Discovery in Space
Sachi Bio has been selected to provide potential scientific and commercialization evidence for use of accelerated aging and...
- Mar 31, 2023
Sachi's NanoligomerTM platform can deliver to the brain with systemic administration
Brain delivery of Nanoligomer using systemic administration What if you could deliver RNA therapeutics to the brain for high-precision...
Subscribe to Our Newsletter
Follow Us On:
© 2024 Sachi Bio
bottom of page